(Bloomberg) -- European stocks posted the biggest weekly decline in over three months, as Danish drugmaker Novo Nordisk A/S sank 21% after a study showed underwhelming results from its obesity drug trial.Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends